Intralesional Chemotherapy for Laryngeal Cancer

DE
Overseen ByDavid E Rosow, MD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to determine the effects, good and bad, of injecting chemotherapy into recurrent laryngeal squamous cell carcinoma (SCC) tumors.

Who Is on the Research Team?

DR

David Rosow, MD

Principal Investigator

University of Miami

Are You a Good Fit for This Trial?

Inclusion Criteria

I have had radiation therapy for laryngeal cancer.
I am willing to have 3 weekly treatments under local anesthesia before surgery.
Willingness to avoid pregnancy based on specified criteria
See 3 more

Exclusion Criteria

Significant concurrent, uncontrolled medical condition
I am unable to make my own medical decisions.
Inability to tolerate awake, unsedated laryngeal procedures
See 10 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive one dose of intralesional chemotherapy treatment per week over a period of approximately 3 weeks

3 weeks
3 visits (in-person)

Surgery

Participants undergo endoscopic surgery for their disease

1 week
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

18 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Cisplatin
  • Epinephrine

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Cisplatin + Epinephrine GroupExperimental Treatment4 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Miami

Lead Sponsor

Trials
976
Recruited
423,000+